Regulators are hopeful that the commission’s actions may clear the way for the opening of state-licensed dispensaries by this spring.
Topic: CBD
Over 90 percent of subjects treated with the combination therapy experienced a ≥50 percent reduction in seizure frequency at six-months.
Patients in the treatment group experienced a decrease in pain of 29 percent over the course of the trial, whereas those in the control group only experienced a six percent decrease.
Investigators concluded, “Well-being, anxiety, sleep disturbance, and pain significantly improved among those assigned to take a CBD product relative to controls.”
Autistic patients exhibited significant improvements in communication and socialization skills, among other improvements.
The study is the largest double-blind, randomized, placebo-controlled clinical trial ever conducted involving FSX patients.
“Patients exhibited significantly faster performance with fewer errors on several tasks of executive function relative to baseline,” investigators concluded.
Investigators concluded, “CBD has a good safety profile, is well tolerated with opioid agonists, and reduces key withdrawal symptoms.”